Research Achievements

Presentations and Posters

Long-term follow-up of neoadjuvant dual anti-HER2 therapy with trastuzumab and lapatinib plus paclitaxel, with or without endocrine therapy for HER2‐positive primary breast cancer: Neo-LaTH (JBCRG-16) study.


Tomomi Fujisawa, Norikazu Masuda, Naohito Yamamoto, Hiroji Iwata, Hiroko Bando, Tomoyuki Aruga, Eriko Tokunaga, Shoichiro Ohtani, Toshimi Takano, Kenichi Inoue, Nobuyasu Suganuma, Masahiro Takada, Kenjiro Aogi, Kenichi


2021.9 ESMO Poster WEB

Genomic profile and response prediction of eribulin mesylate based neoadjuvant chemotherapy in triple negative breast cancer patients


Tomomi Nishimura, Norikazu Masuda, Kosuke Kawaguchi, Masahiro Takada, Yurina Maeshima, Sunao Tanaka, Ravindranath M. Velaga, Yuichiro Kikawa, Takayuki Kadoya, Hiroko Bando, Rikiya Nakamura, Yutaka Yamamoto, Takayuki Ueno, Hiroyuki Yasojima, Hiroshi Ishiguro, Satoshi Morita, Shinji Ohno, Hironori Haga, Seishi Ogawa, Masakazu Toi


2021.9 ESMO Poster WEB

Immune microenvironment, homologous recombination deficiency and therapeutic response to neoadjuvant chemotherapy in triple negative breast cancer: JBCRG22 TR


Takayuki Ueno, Shigehisa Kitano, Norikazu Masuda, Daiki Ikarashi, Makiko Yamashita, Takayuki Kadoya, Hiroko Bando, Takashi Yamashita, Shoichiro Ohtani, Shigenori Nagai, Takahiro, Nakayama, Masato Takahashi, Shigehira Saji, Kenjiro Aogi, Ravindranath M. Velaga, Kosuke Kawaguchi, Satoshi Morita, Hironori Haga, Shinji Ohno, Masakazu Toi


2021.9 ESMO Poster WEB

Longitudinal alteration of cytokine profile in the peripheral blood and clinical response for neoadjuvant chemotherapy in triple-negative breast cancer patients (Translational Research of the JBCRG-22 Trial)


Kosuke Kawaguchi, Norikazu Masuda, Sunao Tanaka, Hiroko Bando, Tomomi Nishimura, Takayuki Kadoya, Takashi Yamanaka, Shigeru Imoto, Ravindranath M. Velaga, Nobuko Tamura, Tomoyuki Aruga, Yurina Maeshima, Masahiro Takada, Eiji Suzuki, Takayuki Ueno, Seishi Ogawa, Hironori Haga, Shinji Ohno, Satoshi Morita, Masakazu Toi


2021.9 ESMO Poster WEB

PRECIOUS: Pertuzumab re-treatment for HER2-positive locally advanced/metastatic breast cancer (JBCRG-M05)


Tatsuya Toyama, Yutaka Yamamoto, Hiroji Iwata, Masato Takahashi, Tetsuhiro Yoshinami, Takayuki Ueno, Takashi Yamanaka, Toshimi Takano, Masahiro Kashiwaba, Norikazu Masuda, Koichiro Tsugawa, Yoshie Hasegawa, Kenji Tamura, Hiroshi Tada, Naruto Taira, Fumikata Hara, Shigehira Saji, Satoshi Morita, Masakazu Toi, Shinji Ohno


2021.3 JSMO Oral WEB

A randomized, open-label, phase III trial of pertuzumab re-treatment in HER2-positive, locally advanced/metastatic breast cancer patients previously treated with pertuzumab, trastuzumab, and chemotherapy: The Japan Breast Cancer Research Group-M05 (PRECIOUS) study


Yutaka Yamamoto, Hiroji Iwata, Taira Naruto, Norikazu Masuda, Masato Takahashi, Tetsuhiro Yoshinami, Takayuki Ueno, Tatsuya Toyama, Takashi Yamanaka, Toshimi Takano, Masahiro Kashiwaba, Koichiro Tsugawa, Yoshie Hasegawa, Kenji Tamura, Hiroshi Tada, Fumikata Hara, Shigehira Saji, Satoshi Morita, Masakazu Toi, Shinji Ohno, Japan Breast Cancer Research Group.


2020.12 SABCS Oral WEB

A randomized, phase 2 study of neoadjuvant chemotherapy containing eribulin mesylate for triple-negative primary breast cancer patients stratified by homologous recombination deficiency status (JBCRG-22)


Hiroko Bando, Norikazu Masuda, Takashi Yamanaka, Takayuki Kadoya, Masato Takahashi, Shigenori Nagai, Shoichiro Ohtani, Tomoyuki Aruga, Eiji Suzuki, Yuichiro Kikawa, Hiroyuki Yasojima, Hiroi Kasai, Hiroshi Ishiguro, Hidetaka Kawabata, Satoshi Morita, Hironori Haga, Tatsuki R.Kataoka, Ryuji Uozumi, Shinji Ohno, Masakazu Toi


2020.9 ESMO Oral WEB

Patient-reported outcomes of a switch to maintenance endocrine therapy following induction chemotherapy versus continuation of chemotherapy in ER-positive HER2-negative metastatic breast cancer: a randomized, open-label, phase 2 clinical trial


S. Saji, N. Taira, S. Morita, M. Kitada, T. Takano, M. Takada, T. Ohtake, T. Toyama, Y. Kikawa, Y. Hasegawa, T. Fujisawa, M. Kashiwaba, T. Ishida, R. Nakamura, Y. Yamamoto, U. Toh, H. Iwata, N. Masuda, S. Ohno and M. Toi


2020.9 ESMO Poster WEB

Pooled-analysis of prospective observational studies evaluated the effectiveness and safety of bevacizumab and paclitaxel as the first-line chemotherapy for HER2-negative metastatic breast cancer


Hiroyasu Yamashiro, Yutaka Yamamoto, Andreas Schneeweiss, Volkmar Müller, Oleg Gluz, Peter Klare, Bahriye Aktas, Dank Magdolna, László Büdi,Béla Pikó, László Mangel, Masakazu Toi, Satoshi Morita, Shinji Ohno


2020.9 ESMO Poster WEB

Outcomes of fulvestrant therapy among Japanese women with ER-positive HER2-positive advanced or metastatic breast cancer: A subgroup analysis of the Japan Breast Cancer Research Group(JBCRG)-C06 Safari study


Misato Hagi, Hidetoshi Kawaguchi, Norikazu Masuda, Shigehira Saji, Yutaka Yamamoto, Takahiro Nakayama, Kenjiro Aogi, Keisei Anan, Yoshinori Ito, Shoichiro Ohtani, Nobuaki Sato, Toshimi Takano, Eriko Tokunaga, Seigo Nakamura, Yoshie Hasegawa, Masaya Hattori, Tomomi Fujisawa, Miki Yamaguchi, Hiroko Yamashita, Toshinari Yamashita, Daisuke Yotsumoto, Satoshi Morita, Masakazu Toi ,Shinji Ohno


2019.12 SABCS Poster San Antonio, Texas

Next Page
Presentations and Posters
by Voluntary Organization JBCRG